comparemela.com

Latest Breaking News On - Bay clinical - Page 1 : comparemela.com

Friday s Afternoon Update

Friday s Afternoon Update

Chimeric Therapeutics Ltd granted European patent for cancer-fighting asset CHM 1101

Chimeric Therapeutics Ltd granted European patent for cancer-fighting asset CHM 1101
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.

Chimeric Therapeutics Ltd forms partnership with OncoBay Clinical to advance CHM1101 development program

Chimeric Therapeutics Ltd forms partnership with OncoBay Clinical to advance CHM1101 development program
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.

OncoBay Clinical Announces Technology Partnership with Protocol First

OncoBay Clinical Announces Technology Partnership with Protocol First OncoBay Adopts Protocol First Technology Solutions to Further Simplify the Complex News provided by Share this article TAMPA, Fla. and SALT LAKE CITY, May 11, 2021 /PRNewswire/ OncoBay Clinical Inc., a full-service boutique contract research organization (CRO) specializing in the simplification of complex oncology programs, today announced a strategic partnership with Protocol First, Inc., a software solutions provider focused on accelerating clinical research. The partnership combines OncoBay s industry leading oncology operations with Protocol First s world class proprietary Clinical Pipe software to integrate data from leading EHR systems into electronic data capture (EDC). The adoption of Clinical Pipe allows OncoBay to further simplify complex oncology trials by improving data quality, reducing data entry timelines, reducing queries as well as the need for on-site monitoring visits to verify source

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.